NDA 017560 · Sun Pharm Industries
Bactrim
Sulfamethoxazole, Trimethoprim · Oral
DiscontinuedLast checked: Nov 20, 2026Latest source record: Feb 21, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1975
Apr 15, 1975
Approved uses
3
Original approval plus efficacy supplements
Registered trials
235
70 Phase 3, 31 recruiting
FAERS reports
70,110
59,125 serious, 8,738 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 15, 1990 Supplement 39 · Efficacy
- Feb 23, 1982 Supplement 18 · Efficacy
- Apr 15, 1975 Original approval · Type 3 - New Dosage Form
2 products under this application
- BACTRIM · SULFAMETHOXAZOLE 200MG/5ML; TRIMETHOPRIM 40MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · SUSPENSION, ORAL · Discontinued
- BACTRIM PEDIATRIC · SULFAMETHOXAZOLE 200MG/5ML; TRIMETHOPRIM 40MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · SUSPENSION, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Sulfamethoxazole" as an intervention, any sponsor and status, largest first.
- Etiology, Prevention and Treatment of Neonatal Infections in the CommunityPivotal-lookingCompleted
Johns Hopkins Bloomberg School of Public HealthAcademic, hospital or other
NCT00198627 · 16,359 participants · Start Dec 2003 · Primary completion Sep 2007
Drug: Co-Trimoxazole; TMP-SMZ · For: Bacterial Infection; Infectious Disease
Sites: Dhaka, Bangladesh
- Study to Improve Survival Among HIV-Exposed Infants in BotswanaPivotal-lookingCompleted
Harvard School of Public Health (HSPH)Academic, hospital or other
NCT01229761 · 3,724 participants (planned) · Start May 2011 · Primary completion Mar 2015
Drug: cotrimoxazole prophylaxis; cotrimoxazole placebo · For: HIV Infections; Neutropenia; Anemia
Sites: Gaborone, Botswana; Lobatse, Botswana; Molepolole, Botswana
- Antibiotic Prophylaxis for Transrectal Prostate Biopsy-Ciprofloxacin vs. Trimethoprim/SulfamethoxazolePivotal-lookingStatus unknown
Umeå UniversityAcademic, hospital or other
NCT02734732 · 2,800 participants (planned) · Start Apr 2015 · Primary completion Apr 2020
Drug: Trimethoprim/Sulfamethoxazole; Ciprofloxacin · For: Prostate Infection
Sites: Östersund, Sweden; Sundsvall, Sweden; Ängelholm, Sweden · 5 sites in all
- A Randomized, Comparative, Prospective Study of Daily Trimethoprim / Sulfamethoxazole (TMS) and Thrice-Weekly TMS for Prophylaxis Against PCP in HIV-Infected PatientsPivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00000748 · 2,500 participants
Drug: Sulfamethoxazole-Trimethoprim · For: Pneumonia, Pneumocystis Carinii; HIV Infections
Sites: San Francisco, California; Stanford, California; Denver, Colorado · 24 sites in all
- Strategies Using Off-Patent Antibiotics for Methicillin Resistant S. Aureus "STOP MRSA"Pivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00729937 · 2,265 participants · Start Apr 2009 · Primary completion May 2013
Drug: Cephalexin; Clindamycin and 1 more · For: Staphylococcal Infection
Sites: Phoenix, Arizona; Sylmar, California; Baltimore, Maryland · 5 sites in all
- ICMR-Indiaclen Trial on Amoxycillin vs Cotrimoxazole for Non-Severe PneumoniaPivotal-lookingCompleted
King George's Medical UniversityAcademic, hospital or other
NCT00396526 · 2,000 participants · Start Apr 2004
Drug: Oral Co-trimoxazole (8mg/kg/day trimithoprim) twice a day for five days vs. oral amoxycillin (20 mg/kg/day) thrice a day for three days. · For: Non-Severe Pneumonia; Under-Fives; Children
Sites: Lucknow, India
- Computer Stop Order Alert to Prevent Concurrent Prescribing of Trimethoprim/Sulfamethoxazole and WarfarinPivotal-lookingTerminated
University of PennsylvaniaAcademic, hospital or other
NCT00870298 · 1,971 participants · Start Aug 2006 · Primary completion Jan 2007
Drug: Trimethoprim/Sulfamethoxazole and Warfarin · For: Prescribers' Drug Orders
- Cotrimoxazole Prophylaxis in Severely Malnourished ChildrenPivotal-lookingCompleted
University of OxfordAcademic, hospital or other
NCT00934492 · 1,781 participants · Start Nov 2009 · Primary completion Apr 2014
Drug: Cotrimoxazole dispersible tablet; Placebo dispersible tablet · For: Nutrition Disorders; Life-threatening Infection
Sites: Kilifi, Kenya; Malindi, Kenya; Mombasa, Kenya · 4 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- pyrexia5,541
- off label use4,378
- fatigue4,197
- diarrhoea4,079
- rash3,910
- nausea3,787
- dyspnoea3,613
- pain3,410
- drug ineffective3,258
- vomiting3,184
- drug hypersensitivity2,987
- pneumonia2,728
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 794 |
| 2005 | 844 |
| 2006 | 907 |
| 2007 | 1,079 |
| 2008 | 1,366 |
| 2009 | 1,512 |
| 2010 | 1,574 |
| 2011 | 2,063 |
| 2012 | 2,088 |
| 2013 | 1,567 |
| 2014 | 2,023 |
| 2015 | 3,264 |
| 2016 | 3,943 |
| 2017 | 4,059 |
| 2018 | 5,403 |
| 2019 | 6,015 |
| 2020 | 5,698 |
| 2021 | 5,120 |
| 2022 | 4,485 |
| 2023 | 4,440 |
| 2024 | 4,849 |
| 2025 | 4,072 |
| 2026 | 2,940 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Bactrim (Sulfamethoxazole/Trimethoprim)
2024 spending
$2K
Beneficiaries
18
36 claims
Per beneficiary
$99
$1.17 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $2,067 |
| 2021 | $1,861 |
| 2022 | $0 |
| 2023 | $1,593 |
| 2024 | $1,780 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative efficacy and safety of Pneumocystis jirovecii pneumonia prophylaxis regimens for people living with HIV: a systematic review and network meta-analysis of randomized controlled trials.
Prosty C, Katergi K, Sorin M, et al. · Clin Microbiol Infect 2024 · Systematic Review, Comparative Study
- Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients.
Stern A, Green H, Paul M, et al. · Cochrane Database Syst Rev 2014 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Comparative efficacy and safety of treatment regimens for Pneumocystis jirovecii pneumonia in people living with HIV: a systematic review and network meta-analysis of randomized controlled trials.
Hatzl S, Posch F, Scholz L, et al. · Clin Microbiol Infect 2025 · Systematic Review, Comparative Study
- Prophylaxis Options in Children With a History of Recurrent Urinary Tract Infections: A Systematic Review.
Gkiourtzis N, Stoimeni A, Glava A, et al. · Pediatrics 2024 · Systematic Review, Meta-Analysis
- Revisiting the Evidence Base for Modern-Day Practice of the Treatment of Toxoplasmic Encephalitis: A Systematic Review and Meta-Analysis.
Prosty C, Hanula R, Levin Y, et al. · Clin Infect Dis 2023 · Meta-Analysis, Systematic Review
- Alterations of human skin microbiome and expansion of antimicrobial resistance after systemic antibiotics.
Jo JH, Harkins CP, Schwardt NH, et al. · Sci Transl Med 2021 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
Sponsor: Sun Pharm Industries · Also marketed as Bactrim Pediatric
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.